Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis

García-Collinot, Grettel; Madrigal-Santillán, Eduardo O.; Martínez-Bencomo, Michel A.; Carranza-Muleiro, Rosa Angélica; Jara, Luis J.; Vera‐Lastra, Olga; Montes-Cortes, Daniel H.; Medina, Gabriela; Cruz-Domínguez, María Pilar

doi:10.1007/s10620-019-05830-0

Cited by 50 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bacterial overgrowth determines malabsorption of fat and vitamins with concomitant production of gas and osmotically active products, which in turn lead to the symptoms of diarrhea, abdominal tenderness, and bloating. Small intestinal bacterial overgrowth is due to delayed gastric emptying and prolonged orofecal transit time and is characterized by an increase in the number and/or an abnormal type of bacteria, which may count up to 60% higher than in healthy controls [28][29][30]. Dysbiosis-related bloating and distension may induce abdominal pain, in turn causing anorexia and reduced food intake [31], thus favoring muscle loss and possibly explaining the mild association between UCLA SCTC GIT 2.0 distention/bloating and low FFMI observed in the present study.…”

Section: Discussionmentioning

confidence: 99%

Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis

et al. 2022

View full text Add to dashboard Cite

Introduction/objectives Gastrointestinal tract (GIT) involvement is frequently observed in systemic sclerosis (SSc) and may lead to nutritional impairment. The aim of the study was to assess the prevalence of symptoms related to GIT involvement and to analyze the possible association between gastrointestinal symptoms and low muscularity in SSc patients. Methods Sixty-nine consecutive patients (60 females, median age 53 (IQR 43–63), body mass index (BMI) 23.2 (IQR 20.9–24.6) kg/m2) with diagnosis of SSc admitted to our Scleroderma Unit were enrolled. Clinical status, anthropometric data, and bioelectrical impedance (Inbody 770, USA) analysis-assessed Fat-Free Mass Index (FFMI) were recorded upon enrollment. UCLA questionnaire was used to quantify GIT involvement with seven specific scales. Results Mean FFMI was 16.2 kg/m2 (IQR 15.2–17.6). The median UCLA total score was 0.53 (IQR 0.19–0.89). FFMI showed a significant negative correlation with UCLA total score (r = −0.29, p = 0.016) and UCLA distention/bloating (r = −0.35, p < 0.01). In 16 patients (23.1%), FFMI was reduced and UCLA distention/bloating was significantly higher (p = 0.039) in SSc patients with lower FFMI [1.75 (IQR 0.75–2.12) vs 0.75 (IQR 0.25–1.75)]. At multiple linear regression model, FFMI showed association with UCLA distention/bloating [beta coefficient − 0.315 (95% CI of beta coefficient: −0.591; −0.039), p = 0.026], BMI [beta coefficient 0.259 (95% CI of beta coefficient: 0.163; 0.355), p = 0.001], and disease duration [beta coefficient − 0.033 (95% CI of beta coefficient: −0.059; −0.007), p = 0.015]. Conclusions In SSc, low FFMI is associated with symptoms related to GIT involvement, in particular with distension/bloating. Key Points• FFMI is associated with symptoms related to GIT involvement.• Low FFMI is associated with symptoms related to UCLA distention/bloating.• Malnutrition is not associated with symptoms related to GIT involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…No autismo apesar das alterações gastrointestinais não serem relatadas na sintomatologia são bastante recorrentes neste público, diversos estudos têm relatado esta característica, evidenciando alterações na microbiota de autistas comparada a indivíduos controle, notificando que há grandes diferenças na composição microbiana (Strati et al, 2017;Kushak et al, 2017;Zhang et al, 2018;Jin et al, 2019;Ma et al, 2019) Gastroenterology Organization, 2017;Miyaoka et al, 2017;Sun et al, 2018;García-Collinot et al, 2020).…”

Section: Disbiose Intestinal No Transtorno Do Espectro Autistaunclassified

Suplementação de prebióticos e probióticos em crianças autistas: revisão integrativa

Brandão

Silva

Campos

et al. 2022

RSD

View full text Add to dashboard Cite

Objetivo: Avaliar o uso da suplementação de probióticos e prebióticos em crianças autistas. Metodologia: Foram identificados artigos nas bases de dados PubMed e SciELO. Para a localização dos estudos foram utilizados descritores em inglês cadastrados no Descritores em Ciências da Saúde (DeCS): Prebiotics. Probiotics. Autism Spectrum Disorder. Gut microbiota. Bifidobacterium. A busca limitou-se a artigos em inglês e compreendeu os anos de publicação entre 2015-2021. Resultados: Um total de 6 ensaios clínicos realizados em crianças com autismo foram revisados sistematicamente. Com relação aos tipos de suplementações utilizadas foram 3 estudos que utilizaram probióticos, 2 que utilizaram prebióticos e probióticos e 1 que fez apenas o uso de prebióticos. Apesar da quantidade escassa de estudos, os mesmos tiveram resultados notáveis com relação à suplementação de probióticos e prebióticos em crianças com Transtorno do Espectro Autista. Em alguns estudos foi possível observar a melhora na gravidade do autismo e melhorias com relação ao comportamento antissocial, já em outros houve o aumento de bactérias benéficas e diminuição das patogênicas no trato gastrintestinal levando a melhora de sintomas gastrointestinais recorrentes. Conclusão: O uso de prebióticos e probióticos apresentam resultados significativos em crianças com TEA, sendo uma terapia alternativa, promissora e complementar. Ainda assim, há a necessidade que mais ensaios clínicos sejam realizados acerca do assunto, pois são escassos e com amostras pequenas.

show abstract

“…In a recent pilot clinical trial conducted in 40 patients with SIBO, after 2 mo of treatment, Saccharomyces boulardii alone and in combination with metronidazole eradicated it (33% and 55%, respectively) compared with metronidazole alone (25%). Additionally, it improved GI symptoms and had fewer adverse effects[ 103 ]. In general, after the administration of multistrain probiotics in patients with GI and SSc symptoms, adverse events are mild[ 104 ].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Gastrointestinal manifestations of systemic sclerosis: An updated review

Lúquez-Mindiola

Atuesta

Aldana

2021

WJCC

View full text Add to dashboard Cite

Systemic sclerosis is an autoimmune disease characterized by vascular disease, fibrosis of the skin, and internal organ dysfunction. Gastrointestinal involvement is the most frequent complication of internal organs, impacting up to 90% of patients. Gastrointestinal involvement can affect any region of the gastrointestinal tract from the mouth to the anus, with a predominance of disorders being observed at the level of the upper digestive tract. The gastrointestinal involvement primarily involves the esophagus, small bowel, and rectum. The severity of gastrointestinal involvement affects quality of life and is a marker of worse prognosis and mortality in these patients. In this review, we describe the current findings regarding gastrointestinal involvement by this entity.

show abstract

Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis

Cited by 50 publications

References 29 publications

Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis

Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis

Suplementação de prebióticos e probióticos em crianças autistas: revisão integrativa

Gastrointestinal manifestations of systemic sclerosis: An updated review

Contact Info

Product

Resources

About